Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05021627
Other study ID # Chest 18
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date August 31, 2026

Study information

Verified date August 2021
Source Shanghai Chest Hospital
Contact Xu Liu, MD
Phone +8613052320103
Email heartlx@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter randomized controlled study. By comparing patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation and pacemaker therapy, and long-term follow-up to evaluate its safety and effectiveness after surgery, in order to evaluate the safety and effectiveness of cardiac autonomic ganglion ablation in the treatment of sinus bradycardia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 240
Est. completion date August 31, 2026
Est. primary completion date August 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Aged 18 to 80 years old; 2. Symptomatic sinus bradycardia; 3. Not meet the class I indications for pacemaker implantation. Exclusion Criteria: 1. Structural heart disease, heart surgery history; 2. Drug-induced SB, sinus pause >2.0 s, positive atropine test, corrected sinus node recovery time (cSNRT) >525 ms; 3. Any atrial or ventricular arrhythmia, or a history of ablation procedures to treat atrial tachyarrhythmias; 4. With Significant congenital heart disease, ejection fraction was <40% measured by echocardiography; 5. Allergic to contrast media; 6. Contraindication to anticoagulation medications; 7. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (COPD); 9. Poor general health; 10.Life expectancy less than 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cardiac autonomic nerve modification
Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP[LSGP]), the leftinfer oposterior area(left inferior GP[LIGP]), the right superoanterior area (rightanterior GP[RAGP]), the right inferoposterior area(right inferior GP[RIGP]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
Pacemaker implantation
Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Shanghai Chest Hospital The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine, The Second People's Hospital of Yuhuan City

Outcome

Type Measure Description Time frame Safety issue
Primary Symptom score after operation Each patient subjectively assessed his or her SB-related symptom, including dizziness, fatigue, and palpitation, on a score of 1 to 10 points (mildtosevere). The total SB-related symptom score for each patient was calculated as the sum of all scores for individual symptoms. 48 months
Secondary Quality of life score The Medical Outcomes Study Short-Form 36 Health Survey (SF-36) was used to assess quality of life (QoL) at baseline and 12 months after ablation. The self-administration mode was strictly followed for QoL surveys. TheSF-36 assesses 8 specific QoL domains, namely physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problem, and mental health. For each subscale, scores were transformed to a scale ranging from 0 to 100, with lower scores representing a lower QoL. 48 months
Secondary Psychological quality score The Zung Self-Rating Depression Scale is a short self administered survey to quantify the depressed status of a patient. There are 20 items on the scale that rate the four common characteristics of depression: the pervasive effect, the physiological equivalents, other disturbances, and psychomotor activities.
There are ten positively worded and ten negatively worded questions. Each question is scored on a scale of 1-4 (a little of the time, some of the time, good part of the time, most of the time).
48 months
See also
  Status Clinical Trial Phase
Recruiting NCT06276816 - Cardiac Denervation Ablation Strategy for Severe Sinus Bradycardia
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Completed NCT02462941 - Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart Phase 1
Active, not recruiting NCT01200667 - uPHI: Wireless Body Area Network Core Technology N/A
Completed NCT02400983 - Real Life Automatic Atrial Capture Device Control N/A
Completed NCT00832260 - IES-ACap: Influence of Atrial Pulse Width in the Behaviour of ACap™ Confirm Algorithm.